Heart Test Laboratories, Inc. (HSCS)
| Market Cap | 7.27M |
| Revenue (ttm) | 10,089 |
| Net Income (ttm) | -6.67M |
| Shares Out | 8.35M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,805 |
| Open | 0.761 |
| Previous Close | 0.781 |
| Day's Range | 0.761 - 0.922 |
| 52-Week Range | 0.710 - 6.000 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 5.61 (+544.83%) |
| Earnings Date | Mar 16, 2023 |
About HSCS
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas. [Read more]
Financial Performance
In 2022, HSCS's revenue was $14,373, a decrease of -43.86% compared to the previous year's $25,604. Losses were -$4.83 million, 96.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for HSCS stock is "Buy." The 12-month stock price forecast is $5.61, which is an increase of 544.83% from the latest price.
News
Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
Southlake, Texas, Jan. 23, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on January 20th, 2023, by HeartSciences (NASDAQ: HSCS; HSCSW), please note that in the second paragraph ...
HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
Southlake, Texas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on ...
HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
Southlake, TX, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on sav...
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmis...
HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms
Southlake, Texas, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on ...
HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
Southlake, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on ...
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on...
HeartSciences' MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification Independent study demonstrates novel AI-ECG algorithm could prov...
HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Patent builds on previously granted U.S. patent as well as ...
HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences' MyoVista Issuance of new reimbursement-...
HeartSciences to Present at the LD Micro Main Event XV on October 26th
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS) (NASDAQ: HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on saving lives by making an ECG (also known a...
HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th
SOUTHLAKE, TX / ACCESSWIRE / October 6, 2022 / Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on applyi...
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista®
HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology to...
HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on...
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year
HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th
Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also kn...
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing
SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative ...